Management ChangeJul 8, 2026, 09:16 AM
NewcelX Appoints Dr. Camillo Ricordi to Scientific Advisory Board
AI Summary
NewcelX Ltd. announced the appointment of Dr. Camillo Ricordi, a globally recognized authority in diabetes cure-focused research and cellular transplantation, to its Scientific Advisory Board. This strategic addition follows the company's successful FDA Type B Pre-IND meeting for NCEL-101, which established a clear regulatory pathway for clinical trials. Dr. Ricordi will provide invaluable expertise to advance NewcelX's Type 1 Diabetes program and its collaboration with Eledon Pharmaceuticals, strengthening the company's scientific leadership.
Key Highlights
- NewcelX appointed Dr. Camillo Ricordi, a leading expert in diabetes research and cellular transplantation, to its Scientific Advisory Board.
- Dr. Ricordi is internationally recognized for his work in beta-cell replacement and cellular transplantation, with over 1,250 scientific publications.
- His appointment follows NewcelX's successful FDA Type B Pre-IND meeting for NCEL-101, providing a clear regulatory pathway for clinical trials.
- Dr. Ricordi will support the advancement of NewcelX's Type 1 Diabetes program and its strategic collaboration with Eledon Pharmaceuticals.
- He currently serves as Chief of the Division of Cellular Transplantation and Director Emeritus of the Diabetes Research Institute.
- Dr. Ricordi invented the Ricordi Chamber for isolating insulin-producing islet cells, a global standard for clinical islet transplantation.
Price Impact
More from NCEL